JP2018506980A5 - - Google Patents

Download PDF

Info

Publication number
JP2018506980A5
JP2018506980A5 JP2017543944A JP2017543944A JP2018506980A5 JP 2018506980 A5 JP2018506980 A5 JP 2018506980A5 JP 2017543944 A JP2017543944 A JP 2017543944A JP 2017543944 A JP2017543944 A JP 2017543944A JP 2018506980 A5 JP2018506980 A5 JP 2018506980A5
Authority
JP
Japan
Prior art keywords
cell
viral vector
composition
capsid protein
capsid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017543944A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018506980A (ja
JP6873907B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/018970 external-priority patent/WO2016134375A1/en
Publication of JP2018506980A publication Critical patent/JP2018506980A/ja
Publication of JP2018506980A5 publication Critical patent/JP2018506980A5/ja
Application granted granted Critical
Publication of JP6873907B2 publication Critical patent/JP6873907B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017543944A 2015-02-20 2016-02-22 遺伝性眼疾患を治療するための方法及び組成物 Active JP6873907B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118934P 2015-02-20 2015-02-20
US62/118,934 2015-02-20
PCT/US2016/018970 WO2016134375A1 (en) 2015-02-20 2016-02-22 Methods and compositions for treating genetic eye diseases

Publications (3)

Publication Number Publication Date
JP2018506980A JP2018506980A (ja) 2018-03-15
JP2018506980A5 true JP2018506980A5 (https=) 2019-04-04
JP6873907B2 JP6873907B2 (ja) 2021-05-19

Family

ID=56689466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017543944A Active JP6873907B2 (ja) 2015-02-20 2016-02-22 遺伝性眼疾患を治療するための方法及び組成物

Country Status (12)

Country Link
US (1) US10472650B2 (https=)
EP (1) EP3261440B1 (https=)
JP (1) JP6873907B2 (https=)
KR (1) KR102655319B1 (https=)
CN (1) CN108347932B (https=)
AU (1) AU2016219789B2 (https=)
CA (1) CA2977355A1 (https=)
ES (1) ES2920850T3 (https=)
SA (1) SA517382162B1 (https=)
SG (1) SG11201706755SA (https=)
WO (1) WO2016134375A1 (https=)
ZA (1) ZA201705628B (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11136557B2 (en) 2013-05-31 2021-10-05 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
JP7046828B2 (ja) 2016-04-15 2022-04-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 滲出型加齢性黄斑変性の治療のための組成物
EP3827812B1 (en) 2016-07-29 2025-10-29 The Regents of the University of California Adeno-associated virus virions with variant capsid and methods of use thereof
WO2018045347A1 (en) * 2016-09-02 2018-03-08 Spark Therapeutics, Inc. Methods and vectors for treating cns disorders
WO2019006182A1 (en) * 2017-06-30 2019-01-03 The Regents Of The University Of California VIRIONS OF ADENO-ASSOCIATED VIRUSES OF CAPSID VARIANTS AND METHODS OF USE THEREOF
JP7221275B2 (ja) 2017-08-03 2023-02-13 ボイジャー セラピューティクス インコーポレイテッド Ａａｖを送達するための組成物および方法
JP2020534788A (ja) 2017-08-28 2020-12-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アデノ随伴ウイルスカプシド変異体及びその使用方法
NZ763617A (en) * 2017-10-16 2026-01-30 Vigeneron Gmbh Aav vectors
SG11202003778QA (en) * 2017-11-13 2020-05-28 Univ California Compositions and methods for enhancing visual function
MA50877A (fr) 2017-11-21 2020-09-30 Bayer Healthcare Llc Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante
CN112105630A (zh) * 2018-02-15 2020-12-18 T·比约尔克隆德 经修饰的病毒衣壳
US12558434B2 (en) 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
US12421525B2 (en) 2018-02-28 2025-09-23 University of Pittsburgh—of the Commonwealth System of Higher Education Conjugates comprising AAVs and CAS9 polypeptides
SG11202011296VA (en) 2018-05-15 2020-12-30 Voyager Therapeutics Inc Compositions and methods for the treatment of parkinson's disease
TW202015742A (zh) 2018-05-15 2020-05-01 美商航海家醫療公司 投遞腺相關病毒（ａａｖ）之組成物和方法
US12060567B2 (en) 2018-06-13 2024-08-13 Voyager Therapeutics, Inc. Engineered untranslated regions (UTR) for AAV production
AU2019310459A1 (en) 2018-07-24 2021-02-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
WO2020072849A1 (en) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
WO2020072844A1 (en) 2018-10-05 2020-04-09 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding aav production proteins
WO2020077165A1 (en) 2018-10-12 2020-04-16 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
CA3116701A1 (en) 2018-10-15 2020-04-23 Voyager Therapeutics, Inc. Expression vectors for large-scale production of raav in the baculovirus/sf9 system
JP2022522995A (ja) 2019-01-18 2022-04-21 ボイジャー セラピューティクス インコーポレイテッド Ａａｖ粒子を生成するための方法及びシステム
EP4667578A3 (en) * 2019-04-03 2026-04-01 REGENXBIO Inc. Gene therapy for eye pathologies
KR20210148333A (ko) * 2019-04-08 2021-12-07 더 칠드런스 호스피탈 오브 필라델피아 Tpp1을 발현하는 aav의 투여를 통한 눈의 리소좀 축적 질환 치료
EP3962536A1 (en) 2019-04-29 2022-03-09 Voyager Therapeutics, Inc. Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2021030125A1 (en) 2019-08-09 2021-02-18 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
TW202122582A (zh) 2019-08-26 2021-06-16 美商航海家醫療公司 病毒蛋白之控制表現
US20220333133A1 (en) 2019-09-03 2022-10-20 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
CN114729009A (zh) * 2019-10-31 2022-07-08 伯尔尼大学 用于眼部基因递送的aav载体变体
CN113025618B (zh) * 2019-12-24 2024-02-06 朗信启昇(苏州)生物制药有限公司 一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
WO2021207500A2 (en) * 2020-04-08 2021-10-14 President And Fellows Of Harvard College TGFβ THERAPY FOR OCULAR AND NEURODEGENERATIVE DISEASES
CN116096734A (zh) 2020-05-13 2023-05-09 沃雅戈治疗公司 Aav衣壳的向性的重定向
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
JP7842082B2 (ja) * 2020-07-21 2026-04-07 エフティージェン コーポレーション 眼疾患を処置するための組成物および方法
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
BR112023001456A2 (pt) 2020-07-27 2023-04-11 Voyager Therapeutics Inc Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
WO2022032153A1 (en) 2020-08-06 2022-02-10 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN113121655B (zh) * 2021-04-19 2021-11-19 上海信致医药科技有限公司 眼部和肌肉特异靶向型腺相关病毒载体及其应用
MX2023012722A (es) * 2021-04-27 2023-11-08 Massachusetts Gen Hospital Capsides de aav y usos de las mismas.
US20240382617A1 (en) * 2021-09-21 2024-11-21 Capsida Biotherapeutics, Inc. Virus compositions to efficiently target the nervous system and the lungs
CA3238867A1 (en) 2021-11-29 2023-06-01 Shanghai Regenelead Therapies Co., Ltd. Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
CN114195859B (zh) * 2021-12-10 2022-11-18 和元生物技术（上海）股份有限公司 一种适用于特异感染u251细胞的腺相关病毒突变体
EP4479414A1 (en) 2022-02-17 2024-12-25 Skyline Therapeutics Limited Recombinant adeno-associated virus with modified aav capsid polypeptides
CN118660913A (zh) 2022-02-21 2024-09-17 上海瑞宏迪医药有限公司 Vegf结合分子及其医药用途
CN119894920A (zh) 2022-07-22 2025-04-25 上海天泽云泰生物医药有限公司 用于靶向神经系统的新型aav衣壳及其用途
US20260085328A1 (en) 2022-09-08 2026-03-26 Voyager Therapeutics, Inc. Controlled expression of viral proteins
EP4688808A1 (en) * 2023-04-04 2026-02-11 Children's Medical Research Institute Aav capsids and vectors for transduction of cells of the peripheral nervous system
WO2025040166A1 (zh) 2023-08-23 2025-02-27 上海瑞宏迪医药有限公司 药物组合物及其用途
WO2025214404A1 (en) 2024-04-10 2025-10-16 Skyline Therapeutics (Shanghai) Co., Ltd. Optogenetic modulation for vision restoration
WO2025214408A1 (en) 2024-04-10 2025-10-16 Skyline Therapeutics (Shanghai) Co., Ltd. Optogenetic modulation for vision restoration
WO2026005189A1 (ko) * 2024-06-27 2026-01-02 이엔셀 주식회사 안구 세포 또는 조직을 표적하는 펩타이드 및 이를 포함하는 바이러스 캡시드 단백질 및 바이러스 벡터
KR102901502B1 (ko) * 2024-06-27 2025-12-18 이엔셀 주식회사 안구 세포 또는 조직을 표적하는 펩타이드 및 이를 포함하는 바이러스 캡시드 단백질 및 바이러스 벡터
CN119039401B (zh) * 2024-08-19 2025-04-11 广州派真生物技术有限公司 腺相关病毒突变体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329501B1 (en) * 1997-05-29 2001-12-11 Auburn University Methods and compositions for targeting compounds to muscle
US6399575B1 (en) * 1998-11-10 2002-06-04 Auburn University Methods and compositions for targeting compounds to the central nervous system
US6943153B1 (en) * 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU2002248297A1 (en) * 2001-01-05 2002-07-16 Children's Hospital, Inc. Aav2 vectors and methods
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US20100081707A1 (en) * 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
US20090215879A1 (en) * 2008-02-26 2009-08-27 University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
KR101154374B1 (ko) * 2009-02-18 2012-07-09 재단법인 아산사회복지재단 표적화된 유전자 전달을 위한 아데노-부속 바이러스 혈청형5 벡터를 포함하는 조성물
US20110052666A1 (en) * 2009-09-03 2011-03-03 Medtronic, Inc. Compositions, Methods, and Systems for SIRNA Delivery
HRP20171334T1 (hr) * 2011-04-22 2017-11-17 The Regents Of The University Of California Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe
WO2013159036A1 (en) * 2012-04-19 2013-10-24 Oregon Health & Science University Adeno associated virus plasmids and vectors
US9567376B2 (en) * 2013-02-08 2017-02-14 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies

Similar Documents

Publication Publication Date Title
JP2018506980A5 (https=)
Drag et al. Gene therapy for retinal degenerative diseases: progress, challenges, and future directions
JP7007273B2 (ja) 遺伝子治療用の改良された複合型二重組換えａａｖベクターシステム
US20220002749A1 (en) Multiple vector system and uses thereof
ES2704677T3 (es) Suministro eficaz de genes grandes por vectores de AAV duales
JP2021097675A (ja) 中枢神経系を標的化したａａｖベクター
EP3413928B1 (en) Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
EP3013946B1 (en) Methods for expressing a polynucleotide of interest in the retina of a subject
US20090011040A1 (en) Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
AU2017227776C1 (en) AAV vectors for treatment of dominant retinitis pigmentosa
JP2018506980A (ja) 遺伝性眼疾患を治療するための方法及び組成物
CA3182080A1 (en) Viral vectors for the treatment of retinal dystrophy
JP2022529782A (ja) シュタルガルト病（ａｂｃａ４）の遺伝子治療
WO2021076941A9 (en) Gene therapy for alzheimer's disease
US20250026795A1 (en) Functional aav capsids for intravitreal administration
Agrawal et al. Ocular Delivery of Viral Vectors for Retinal and Choroidal Vascular Diseases: A Review
US20230066585A1 (en) Gene therapy for treatment of crx-autosomal dominant retinopathies
US20260041791A1 (en) Compositions and methods for treatment of achromotopsia
JP2026503049A (ja) 眼疾患のための遺伝子療法
WO2025231487A1 (en) Photoreceptor specific promotors for use in gene therapies for treatment of retinal degeneration
Class et al. Patent application title: Methods for Expressing a Polynucleotide of Interest in the Retina of a Subject Inventors: Deniz Dalkara (Paris, FR) Alvaro Rendon Fuentes (Paris, FR) Jose Alain Sahel (Paris, FR) Ophelie Vacca (Paris, FR)
Shukla et al. Site-Specific Ocular Nucleic Acid Delivery